A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis
Latest Information Update: 01 Aug 2025
At a glance
- Drugs AZD 2389 (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms BORANA
- Sponsors AstraZeneca
Most Recent Events
- 17 Jul 2025 Planned End Date changed from 8 Dec 2025 to 10 Sep 2025.
- 17 Jul 2025 Planned primary completion date changed from 8 Dec 2025 to 10 Sep 2025.
- 17 Jul 2025 Status changed from recruiting to active, no longer recruiting.